Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats

Pharmacology Biochemistry and Behavior

Volumn 91, Issue 3, 2009, Pages 461-467

  LeSage, Mark G ^a,b   Shelley, David ^a   Ross, Jason T ^a   Carroll, F Ivy ^d   Corrigall, William A ^a,c  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

4 2 nicotinic acetlycholine receptor; Cytisine; Drug discrimination; Nicotine; Partial agonist; Varenicline

Indexed keywords

CYTISINE; NICOTINE; NICOTINIC RECEPTOR; PARTIAL AGONIST; VARENICLINE;

ANIMAL EXPERIMENT; ARTICLE; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALKALOIDS; ANIMALS; AZOCINES; BENZAZEPINES; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; GENERALIZATION, STIMULUS; MALE; NICOTINE; NICOTINIC AGONISTS; QUINOLIZINES; QUINOXALINES; RATS; RATS, LONG-EVANS; RECEPTORS, NICOTINIC;

NICOTIANA TABACUM; RATTUS;

EID: 57449094969     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.08.024     Document Type: Article

References (49)

1. Brioni J.D., Kim D.J., O'Neill A.B., Williams J.E., and Decker M.W. Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res 643 (1994) 1-9
2. Brioni J.D., Kim D.J., and O'Neill A.B. Nicotine cue: lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine. Eur J Pharmacol 301 (1996) 1-5
3. Brooks P.R., Caron S., Coe J.W., Ng K.K., Singer R.A., Vazquez E., et al. Synthesis of 2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepine via oxidative cleavage and reductive amination strategies. Synthesis 11 (2004) 1755-1758
4. Cahill K., Stead L.F., and Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (2007) CD006103
5. Chandler C.J., and Stolerman I.P. Discriminative stimulus properties of the nicotinic agonist cytisine. Psychopharmacology (Berl) 129 (1997) 257-264
6. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48 (2005) 3474-3477
7. Coe J.W., Vetelino M.G., Bashore C.G., Wirtz M.C., Brooks P.R., Arnold E.P., et al. In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg Med Chem Lett 15 (2005) 2974-2979
8. Corrigall W.A., and Coen K.M. Nicotine maintains robust self-administration in rats on a limited- access schedule. Psychopharmacology 99 (1989) 473-478
9. Corrigall W.A., Franklin K.B., Coen K.M., and Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107 (1992) 285-289
10. Corrigall W.A., Coen K.M., and Adamson K.L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653 (1994) 278-284
11. Craft R.M., and Howard J.L. Cue properties of oral and transdermal nicotine in the rat. Psychopharmacology (Berl) 96 (1988) 281-284
12. Etter J.F., Lukas R.J., Benowitz N.L., West R., and Dresler C.M. Cytisine for smoking cessation: a research agenda. Drug Alcohol Depend 92 (2008) 3-8
13. Evans N.M., Bose S., Benedetti G., Zwart R., Pearson K.H., McPhie G.I., et al. Expression and functional characterization of a human chimeric nicotinic receptor with alpha6beta4 properties. Euro J Pharmacol 466 (2003) 31-39
14. Fiore M.C., Jaen C.R., and Baker T.B. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline (2008), U.S. Department of Health and Human Services, Rockville, MD
15. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 164 (2007) 1269
16. Gommans J., Stolerman I.P., and Shoaib M. Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 39 (2000) 2840-2847
17. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 47-55
18. Gotti C., and Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74 (2004) 363-396
19. Green T.A., Phillips S.B., Crooks P.A., Dwoskin L.P., and Bardo M.T. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats. Psychopharmacology (Berl) 152 (2000) 289-294
20. Houlihan L.M., Slater Y., Guerra D.L., Peng J.H., Kuo Y.P., Lukas R.J., et al. Activity of cytisine and its bominated isosteres on recombinant human alpha7, alpha4beta2 and alpha4beta4 nicotinic acetylcholine receptors. J Neurochem 78 (2001) 1029-1043
21. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 56-63
22. Kohen I., and Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 164 (2007) 1269-1270
23. Kristensen P.L., Pedersen-Bjergaard U., and Thorsteinsson B. Varenicline may trigger severe hypoglycaemia in Type 1 diabetes. Diabet Med 25 (2008) 625-626
24. Laviolette S.R., and van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5 (2004) 55-65
25. Lerman C., LeSage M.G., Perkins K.A., O'Malley S.S., Siegel S.J., Benowitz N.L., et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6 (2007) 746-762
26. LeSage M.G., Keyler D.E., Shoeman D., Raphael D., Collins G., and Pentel P.R. Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine. Pharmacol Biochem Behav 72 (2002) 279-289
27. LeSage M.G., Keyler D.E., Collins G., and Pentel P.R. Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology (Berl) 170 (2003) 278-286
28. LeSage M.G., Keyler D.E., and Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J 8 (2006) E65-75
29. Luetje C.W., and Patrick J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neuroscience 11 (1991) 837-845
30. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70 (2006) 801-805
31. Mironi M., and Bermudez I. Stoichiometry and pharmacology of two human α4β2 nicotinic receptor types. J Mol Neurosci 30 (2006) 95-96
32. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166 (2006) 1561-1568
33. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C.B., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166 (2006) 1571-1577
34. Philibin S.D., Vann R.E., Varvel S.A., Covington III H.E., Rosecrans J.A., James J.R., et al. Differential behavioral responses to nicotine in Lewis and Fischer-344 rats. Pharmacol Biochem Behav 80 (2005) 87-92
35. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
36. Pratt J.A., Stolerman I.P., Garcha H.S., Giardini V., and Feyerabend C. Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor. Psychopharmacology (Berl) 81 (1983) 54-60
37. Reavill C., Walther B., Stolerman I.P., and Testa B. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 29 (1990) 619-624
38. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 (2007) 985-994
39. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., and Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28 (2007) 316-325
40. Rosecrans J.A. Nicotine as a discriminative stimulus: a neurobehavioral approach to studying central cholinergic mechanisms. J Subst Abuse 1 (1989) 287-300
41. Slater Y.E., Houlihan L.M., Maskell P.D., Exley R., Bermudez I., Lukas R.J., et al. Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 44 (2003) 503-515
42. Smith J.W., Mogg A., Tafi E., Peacey E., Pullar I.A., Szekeres P., et al. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 190 (2007) 157-170
43. Stairs D.J., Neugebauer N.M., Wei X., Boustany C., Hojahmat M., Cassis L.A., et al. Effects of nornicotine enantiomers on intravenous S(-)-nicotine self-administration and cardiovascular function in rats. Psychopharmacology (Berl) 190 (2007) 145-155
44. Stolerman I.P., Garcha H.S., Pratt J.A., and Kumar R. Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology (Berl) 84 (1984) 413-419
45. Stolerman I.P., Chandler C.J., Garcha H.S., and Newton J.M. Selective antagonism of behavioural effects of nicotine by dihydro-beta-erythroidine in rats. Psychopharmacology (Berl) 129 (1997) 390-397
46. Stolerman I.P., Chamberlain S., Bizarro L., Fernandes C., and Schalkwyk L. The role of nicotinic receptor alpha 7 subunits in nicotine discrimination. Neuropharmacology 46 (2004) 363-371
47. Tapper A.R., McKinney S.L., Nashmi R., Schwarz J., Deshpande P., Labarca C., et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306 (2004) 1029-1032
48. Watkins S.S., Epping-Jordan M.P., Koob G.F., and Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62 (1999) 743-751
49. Wonnacott S., Sidhpura N., and Balfour D.J. Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 5 (2005) 53-59